Glioblastoma Treatment Drugs Market
Government’s Initiatives Plans Strengthening Healthcare Sector in the Glioblastoma Treatment Drugs. Explore More Trends
Glioblastoma Treatment Drugs Market by Drug Class, Distribution Channel & Region - Forecast 2022-2032
Glioblastoma Treatment Drugs Market Outlook (2022-2032)
[333 Pages Report] The glioblastoma treatment drugs market is likely to secure a CAGR of 5.7% during the forecast period. The market is projected to be valued at US$ 723.30 million in 2022 and is expected to be valued at US$ 1,259.13 million by 2032.
The demand for glioblastoma treatment drugs is rising due to increasing geriatric populations and increasing incidence cases in recent years. The adoption of glioblastoma treatment drugs is rising with the increasing number of brain cancer tumour patients.
Moreover, some patients get beneficial clinic trials with the receiving development agents. The biomarkers seem to be more successful in personalized medicine for these patients.
|
Report Attribute |
Details |
|
Glioblastoma Treatment Drugs Market Value (2022) |
US$ 723.30 Million |
|
Glioblastoma Treatment Drugs Market Anticipated Value (2032) |
US$ 1,259.13 Million |
|
Glioblastoma Treatment Drugs Projected Growth Rate (2032) |
5.7% |
This tumor is also found in the spinal cord and represents about 15.4% of all primary brain tumors, which increases the demand for glioblastoma treatment drugs. Glioblastoma is difficult to treat because of the number of different types of cells and, thus, various treatment plans combined.
In addition, drugs involved in treating glioblastoma are antineoplastic cytotoxic drugs. There is a significant development in chemotherapy drugs to treat malignant tumors, and each year there are new drugs on the market to overcome the blood-brain barrier.
Moreover, the manufacturers are playing a crucial role in developing and research several drugs for patient treatment that are likely to increase the glioblastoma treatment drugs market share during the forecast period.
Let us know your requirement to get
100% FREE customization
Essential Drives and Constraint Factors in the Glioblastoma Treatment Drugs Market
Glioblastoma is a complicated disease, and thus the treatment for it involves various approaches combining various treatments, which is the major market driver for the glioblastoma treatment drugs market. Treating such tumours is a challenge, which forces researchers to look for diagnoses and newer chemotherapy drugs.
Changing demography, access to healthcare facilities and financial demands are some factors which are lagging in the further developments of glioblastoma. Gaining a better understanding of this disease and efficient treatment improvise, which is only possible through developments in molecular mechanisms, and clinical trials, leading to more promising and tailored therapeutic approaches.
Regional Insights:
An Eagle Eye on North America Glioblastoma Treatment Drugs Market
Among all the regions, the market is segmented into North America, Latin America, Europe, Asia Pacific and MEA. North America dominates the market by acquiring 36% of the share during the forecast period. One of the main drivers of the regional market growth is government support for the growth of the healthcare industry, as well as high awareness of uncommon conditions, easy access to high-quality medical facilities, and kind reimbursement policies.
Worldwide, there are an estimated 240,000 cases related to brain cancer, and glioblastoma is the most common and lethal disease. Every year in the U.S, there are about 18000 people diagnosed with glioblastoma disease, which has accelerated the glioblastoma treatment drugs market growth in recent years.
Examine European Glioblastoma Treatment Drugs
Europe is likely to hold the second position in the glioblastoma treatment drug market by acquiring 27% of the share during the forecast period. However, in European countries, 25000 cases are reported. Therefore there are prime incidences of this disease, which boost the market share in the region.
Moreover, various treatments are coming forward which can be used alone or in combination with radiotherapy and chemotherapy, but there are chances of reappearance. The UK is a leading country, which highlights the market due to the rising number of chemo patients in the country.
For the long-term survival of glioblastoma, there are newer combination therapies studied, and various clinical trials are to fight against this disease. These are propelling the growth of the glioblastoma treatment drugs market during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystKey Trends in Glioblastoma Treatment Drugs
Recently, Merck & Company's temozolomide drug was preferred and approved by the FDA for patient chemotherapy. However, bevacizumab is a treatment drug which targets VEGF-A in brain therapy patients in their early-stage trial. Bevacizumab is an anti-drug that helps to interfere in the development of blood vessels that grow a tumor. It is one of the most effective drugs approved by the FDA and is widely used to treat glioblastoma.
The U.S. FDA authorized Pfizer's Zirabev, a biosimilar to Avastin, in June 2019 for the treatment of recurring cancers, including colorectal, NSCLC, and glioblastoma. The firm introduced its product in the United States in January 2020.
Additionally, the U.S. FDA approved Samsung's BLA application for its SB8 bevacizumab biosimilar candidate in November 2019, increasing the likelihood that products may be released in the upcoming years.
The U.S. FDA granted fast-track designation to Denovo Biopharma's DB102 (enzastaurin) in July 2020 for the treatment of people who have just received a glioblastoma diagnosis.
Competitive Landscape:
How are Key Players Advancing the Glioblastoma Treatment Drugs Market?
The key players are the main drivers of the market, who have played a crucial role in uplifting the market size in recent years. These players are using several marketing tactics to boost the market by acquiring the lion’s share during the forecast period.
Some of the marketing methodologies adopted by them are mergers, product launches, partnerships, collaborations and others.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Recent Developments in the Glioblastoma Treatment Drugs Market
Some of the developments in glioblastoma are currently under research by prominent manufacturers, as follows:
- Gene therapy
- Theraphy on specific tumor - Afatinib, Aldoxorubicin, CBL0137, Val-083
- Kinase inhibitor
- Immunotherapy vaccines - Prophage, DCVax-L, Rindopepimut, Gliovac
- Glioma stem cell targeting
- Virus
- MiRNA targeting
- Others
These are the under-processing development therapies which are likely to be developed by experts and R&D teams in the coming years. The manufacturers are popping out year-on-year with a unique & advanced therapy for glioblastoma treatment.
- In 2019, Merck company acquired Peloton Therapeutics, which is a bio-therapeutic clinical-stage company. The acquisition helps to treat brain cancer with the strongly developed small molecule to treat hypoxia-inducible factor-2α (HIF-2α). Therefore, these help to treat cancer treatment with more strengthening and are boosting the market size of glioblastoma treatment drugs all around the globe.
- Lineage Cell Therapeutics and Immunomic Therapeutics came into a licensing deal in April 2021 for the creation of the allogeneic VAC cancer immunotherapy platform, which is used to treat glioblastoma multiform. According to the deal, Lineage received a USD 2 million upfront payment, as well as USD 67 million in commercial milestone payments.
Key Players in the Glioblastoma Treatment Drugs Market are
- F. Hoffmann-La Roche AG,
- Merck & Co., Inc.,
- Sandoz
- Arbor Pharms LLC.
- Emcure Pharmaceuticals Ltd.
- Bristol-Myers Squibb Company
- Sigma-Tau Pharmaceuticals, Inc.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 5.7% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments:
Based on the Drug Class:
- Antineoplastic
- VEGF/VEGFR Inhibitors
- Alkylating Agents
- Miscellaneous Antineoplastic
Based on the Distribution Channel:
- Hospitals
- Cancer Research Organizations
- Long Term Care Centers
- Diagnostic Centers
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
Frequently Asked Questions
The glioblastoma treatment drugs market is predicted to advance at a CAGR of 5.7% from 2022-to 2032.
North America is anticipated to lead the glioblastoma treatment drugs market during the forecast period.
The glioblastoma treatment drugsmarket is likely to hold a valuation of US$ 1,259.13 million by 2032
The hospital sector is the key driver in the glioblastoma treatment drugs market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class , 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class , 2022-2032
5.3.1. Antineoplastic
5.3.2. VEGF/VEGFR Inhibitors
5.3.3. Alkylating Agents
5.3.4. Miscellaneous Antineoplastic
5.3.5. Digital Input Output
5.4. Y-o-Y Growth Trend Analysis By Drug Class , 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class , 2022-2032
6. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
6.3.1. Hospitals
6.3.2. Cancer Research Organizations
6.3.3. Long Term Care Centers
6.3.4. Diagnostic Centers
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
7. Global Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Oceania Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. MEA Glioblastoma Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Glioblastoma Treatment Drugs Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Drug Class
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Drug Class
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Drug Class
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Drug Class
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Drug Class
15.5.2.2. By Distribution Channel
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Drug Class
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Drug Class
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Drug Class
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Drug Class
15.9.2.2. By Distribution Channel
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Drug Class
15.10.2.2. By Distribution Channel
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Drug Class
15.11.2.2. By Distribution Channel
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Drug Class
15.12.2.2. By Distribution Channel
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Drug Class
15.13.2.2. By Distribution Channel
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Drug Class
15.14.2.2. By Distribution Channel
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Drug Class
15.15.2.2. By Distribution Channel
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Drug Class
15.16.2.2. By Distribution Channel
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Drug Class
15.17.2.2. By Distribution Channel
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Drug Class
15.18.2.2. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Drug Class
15.19.2.2. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Drug Class
15.20.2.2. By Distribution Channel
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2021
15.21.2.1. By Drug Class
15.21.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. F. Hoffmann-La Roche AG
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Merck & Co., Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Sandoz
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Arbor Pharms LLC.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Emcure Pharmaceuticals Ltd.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Bristol-Myers Squibb Company
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Sigma-Tau Pharmaceuticals, Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Cipla Ltd.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Hikma Pharmaceuticals PLC
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Teva Pharmaceutical Industries Ltd,
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 3: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 4: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 5: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 6: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 7: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 9: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 10: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 11: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 12: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 13: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 15: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 16: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 18: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 19: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 20: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 21: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 22: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 23: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Drug Class , 2017-2032
Table 24: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 2: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 3: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 8: Global Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 9: Global Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 10: Global Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 11: Global Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 12: Global Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 13: Global Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 14: Global Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 15: Global Glioblastoma Treatment Drugs Market Attractiveness by Region, 2022-2032
Figure 16: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 17: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 18: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 20: North America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 23: North America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 24: North America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 25: North America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 26: North America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 27: North America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 28: North America Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 29: North America Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 30: North America Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 32: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 33: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 35: Latin America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 38: Latin America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 39: Latin America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 40: Latin America Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 41: Latin America Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 42: Latin America Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 43: Latin America Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 44: Latin America Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 45: Latin America Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Figure 46: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 47: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 48: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 50: Europe Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 53: Europe Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 54: Europe Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 55: Europe Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 56: Europe Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 57: Europe Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 58: Europe Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 59: Europe Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: Europe Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Figure 61: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 62: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 63: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 64: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 65: South Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: South Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 68: South Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 69: South Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 70: South Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 71: South Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 72: South Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 73: South Asia Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 74: South Asia Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 75: South Asia Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Figure 76: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 77: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 78: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 79: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 80: East Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: East Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 83: East Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 84: East Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 85: East Asia Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 86: East Asia Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 87: East Asia Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 88: East Asia Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 89: East Asia Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 90: East Asia Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Figure 91: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 92: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 93: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 94: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 95: Oceania Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 96: Oceania Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 97: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 98: Oceania Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 99: Oceania Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 100: Oceania Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 101: Oceania Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 102: Oceania Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 103: Oceania Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 104: Oceania Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 105: Oceania Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Figure 106: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) by Drug Class , 2022-2032
Figure 107: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 108: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 109: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 110: MEA Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 111: MEA Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 112: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Drug Class , 2017-2032
Figure 113: MEA Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Drug Class , 2022-2032
Figure 114: MEA Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Drug Class , 2022-2032
Figure 115: MEA Glioblastoma Treatment Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 116: MEA Glioblastoma Treatment Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 117: MEA Glioblastoma Treatment Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 118: MEA Glioblastoma Treatment Drugs Market Attractiveness by Drug Class , 2022-2032
Figure 119: MEA Glioblastoma Treatment Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 120: MEA Glioblastoma Treatment Drugs Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
